Remicade?

What is Remicade used for?

Remicade is a biologic treatment used to manage various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis [1]. It belongs to a class of drugs known as tumor necrosis factor (TNF) inhibitors, which work by blocking the action of TNF, a protein that promotes inflammation in the body.

How does Remicade work?

Remicade, also known as infliximab, binds to TNF in the body, preventing it from interacting with its receptors and triggering inflammation. This reduces the symptoms of autoimmune diseases and prevents further damage to the affected tissues [2].

Patent and exclusivity

Remicade was first approved by the FDA in 1998 and held an exclusivity status for a long time [3]. However, in 2018, the first biosimilar version of Remicade, Inflectra, was approved by the FDA, and several other biosimilars have since been introduced to the market [4]. According to DrugPatentWatch.com, the patent for Remicade expired in 2022 [5].

Side effects and warnings

Remicade can cause various side effects, including infections, allergic reactions, and an increased risk of certain types of cancer [6]. Patients taking Remicade should be closely monitored by their healthcare providers and report any signs of infection or other side effects promptly.

Why are companies challenging the Remicade patent?

Companies have challenged the Remicade patent as the patent approached expiration, leading to the approval of biosimilars. This allowed other companies to enter the market, introducing competition and potentially reducing costs for patients.

References

[1] Johnson & Johnson. (2023). REMICADE (Infliximab). [WWW Document].
[2] Infliximab. (n.d.). In StatPearls. StatPearls Publishing.
[3] Food and Drug Administration. (2023). REMICADE.
[4] Inflectra. (2023). FDA. FDA.
[5] DrugPatentWatch.com. (2023). Remicade (Infliximab) Patent Expiration.
[6] REMICADE (Infliximab) prescribing information.